Key Drivers
- Balance-sheet repair
- Persistent losses
- Negative cash flow
AIAI Summary
ALMR should now be viewed less as a pure science-story and more as an early recurring-revenue platform with real commercial traction and a much stronger balance sheet, but the investment case still hinges on proving operating leverage as heavy losses and negative free cash flow make execution—not survival—the main risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Balance-sheet repair
- •Persistent losses
- •Negative cash flow
ALMR has significantly repaired its balance sheet and liquidity, but ongoing operating losses and negative cash flow mean the turnaround is still not yet backed by earnings. #balance-sheet #cash-burn
Price Behavior
Key Price Behavior Insights:
- •Breakout Trend
- •$28 Support
- •Spike Reversal
ALMR has broken into a strong uptrend over the last month, holding above $28 support but showing overbought volatility after a sharp spike to $36.57 and quick pullback.
Sharp spike to $36.57 followed by an immediate drop, signaling volatile profit-taking
Sentiment & News
Key News Insights:
- •Panel expansion
- •Revenue surge
- •Consumables strength
Alamar Biosciences is showing strong momentum, with a new 340-protein immune panel, a global partnership expansion, and Q2 revenue jumping 82% year over year on rising consumables and instrument adoption.
The news is bullish for ALMR, as expanding assay breadth and recurring consumables growth suggest improving platform adoption and durable revenue momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings